Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease

References

• Balzarotti M, Wiernik P H, Santoro A. Diagnosis and treatment of Hodgkin's disease. Neoplastic Diseases of the Blood4th edn., P H Wiernik, J M Goldman, J P Dutcher, R A Kyle. Cambridge University Press, New York, NY 2003; 862–892
   Google Scholar
• Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med 1986; 104: 739–746
   PubMed Web of Science ®Google Scholar
• Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5: 27–37
   PubMed Web of Science ®Google Scholar
• Wiernik P H, Schiffer C A. Long-term follow-up of advanced Hodgkin's disease patients treated with a combination of streptozotocin, lomustine (CCNU), doxorubicin and bleomycin (SCAB). J Cancer Res Clin Oncol 1988; 114: 105–107
   PubMed Web of Science ®Google Scholar
• Longo D L, Duffey P L, DeVita V T, Jr, et al. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. J Clin Oncol 1991; 9: 1409–1420
   PubMed Web of Science ®Google Scholar
• Levi J A, Wiernik P H, Diggs C H. Combination chemotherapy of advanced previously treated Hodgkin's disease with streptozotocin, CCNU, adriamycin and bleomycin. Med Pediatr Oncol 1977; 3: 33–40
   PubMedGoogle Scholar
• Benjamin R S, Chawla S P, Ewer M S, Carrasco C H, Mackay B, Holmes F. Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update. Invest New Drugs 1985; 3: 117–121
   PubMed Web of Science ®Google Scholar
• Dutcher J P, Wiernik P H, Einzig A I, Sparano J, Frank M, Friedenberg W. Mitoxantrone, vinblastine and CCNU (MVC): a highly active regimen in poor prognosis Hodgkin's disease. Blood 1993; 82: 143
   Google Scholar
• Dutcher J P, Wiernik P H. Mitoxantrone, Vinblastine and CCNU (MVC): a highly active regimen in poor prognosis Hodgkin's disease. Proceedings of the VI International Conference on Malignant Lymphoma, Lugano, 5 – 8 June 1996. Ann Oncol 1996; 7: 115
   Google Scholar
• Cooper M R, Spurr C L, Glidewell O, et al. The superiority of a nitrosourea (CCNU) containing four drug combination over MOPP in the treatment of stage III and IV Hodgkin's disease. Blood 1975; 46: 1014–1019
   Web of Science ®Google Scholar
• Wiernik P H, Dutcher J P, Einzig A I, Sparano J, Frank M, Friedenberg W. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease. Cancer J Sci Am 1998; 4: 254–260
   PubMed Web of Science ®Google Scholar
• Hansen H H, Selawry O S, Pajak T F, Spurr C L, Falkson G, Brunner K. The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study. Cancer 1981; 47: 14–18
   PubMed Web of Science ®Google Scholar
• Wiernik P H, Wang S Q, Hu X P, Marino P, Paietta E. Age of onset evidence for anticipation in familial non-Hodgkin's lymphoma. Br J Haematol 2000; 108: 72–79
   PubMed Web of Science ®Google Scholar
• Ashigbi M Y, Venkatraj U, Agarwal V, Bello J, Wiernik P M. Intracranial Hodgkin's disease in two patients with familial Hodgkin's disease. Med Pediatr Oncol 1997; 28: 255–258
   PubMedGoogle Scholar
• Schmitz N, Pfistner B, Sextro M, Sieber M, Carella A M, Haenel M, et al. German Hodgkin's Lymphoma Study Group; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065–2071
   PubMed Web of Science ®Google Scholar
• Ferme C, Mounier N, Divine M, Brice P, Stamatoullas A, Reman O, et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 2002; 20: 467–475
   PubMed Web of Science ®Google Scholar
• Yuen A R, Rosenberg S A, Hoppe R T, Halpern J D, Horning S J. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997; 89: 814–822
   PubMed Web of Science ®Google Scholar
• Levi J A, Wiernik P H, Diggs C H. Combination chemotherapy of advanced previously treated Hodgkin's disease with streptozotocin, CCNU, adriamycin and bleomycin. Med Pediatr Oncol 1977; 3: 33–40
   PubMedGoogle Scholar
• Sutcliffe S B, Wrigley P F, Stansfeld A G, Malpas J S. Adriamycin, bleomycin, vinblastine and imidazole carboxamide (ABVD) therapy for advanced Hodgkin's disease resistant to mustine, vinblastine, procarbazine and prednisolone (MVPP). Cancer Chemother Pharmacol 1979; 2: 209–213
   PubMed Web of Science ®Google Scholar
• Gassmann W, Perenyi L, Pralle H, Graubner M, Schmitz N, Loffler H. Results of treatment with ABVD in C-MOPP-resistant Hodgkin's disease. Klin Wochenschr 1981; 59: 267–273
   PubMedGoogle Scholar
• Santoro A, Bonfante V, Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med 1982; 96: 139–143
   PubMed Web of Science ®Google Scholar
• Straus D J, Myers J, Koziner B, Lee B J, Clarkson B D. Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV). Cancer Chemother Pharmacol 1983; 11: 80–85
   PubMed Web of Science ®Google Scholar
• Piga A, Ambrosetti A, Todeschini G, Cetto G, Perona G, Cellerino R. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease. Cancer Treat Rep 1984; 68: 947–951
   PubMedGoogle Scholar
• Santoro A, Viviani S, Valagussa P, Bonfante V, Bonadonna G. CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease. Semin Oncol 1986; 13: 23–26
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M G, Schoppe W D, Fuchs R, Pfluger K H, Loeffler M, Diehl V. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group. Cancer Treat Rep 1987; 71: 1203–1207
   PubMedGoogle Scholar
• Cabanillas F, Velasquez W S, McLaughlin P, Jagannath S, Hagemeister F B, Redman J R, et al. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. Semin Hematol 1988; 25: 47–50
   PubMed Web of Science ®Google Scholar
• Brusamolino E, Orlandi E, Canevari A, Morra E, Castelli G, Alessandrino E P, et al. Results of CAV regimen (CCNU, melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease. Ann Oncol 1994; 5: 427–432
   PubMed Web of Science ®Google Scholar
• Brice P, Bastion Y, Divine M, Nedellec G, Ferrant A, Gabarre J, et al. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients. Cancer 1996; 78: 1293–1299
   PubMed Web of Science ®Google Scholar
• Andre M, Henry-Amar M, Pico J L, Blaise D, Kuentz M, Coiffier B, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Societe Francaise de Greffe de Moelle. J Clin Oncol 1999; 17: 222–229
   PubMed Web of Science ®Google Scholar
• Bonfante V, Viviani S, Devizzi L, Russo A, Di Nicola M, Magni M, et al. High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease. Eur J Haematol Suppl 2001; 64: 51–55
   PubMedGoogle Scholar
• Zinzani P L, Tani M, Molinari A L, Stefoni V, Zuffa E, Alinari L, et al. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Haematologica 2002; 87: 816–821
   PubMed Web of Science ®Google Scholar
• Cabanillas F, Velasquez W S, McLaughlin P, Jagannath S, Hagemeister F B, Redman J R, et al. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. Semin Hematol 1988; 25: 47–50
   PubMed Web of Science ®Google Scholar
• Spinolo J A, Jagannath S, Velasquez W, Spitzer G, Cabanillis F, Hagemeister F, et al. Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease. Leuk Lymphoma 1993; 9: 71–77
   PubMed Web of Science ®Google Scholar
• Chopra R, McMillan A K, Linch D C, Yuklea S, Taghipour G, Pearce R, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993; 81: 1137–1145
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M G, Rueffer U, Lathan B, Schmitz N, Brosteanu O, Hasenclever D, et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. J Clin Oncol 1994; 12: 580–586
   PubMed Web of Science ®Google Scholar
• Reece D E, Barnett M J, Shepherd J D, Hogge D E, Klasa R J, Nantel S H, et al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV ± P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 1995; 86: 451–456
   PubMed Web of Science ®Google Scholar
• Bierman P J, Anderson J R, Freeman M B, Vose J M, Kessinger A, Bishop M R, et al. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. Ann Oncol 1996; 7: 151–156
   PubMed Web of Science ®Google Scholar
• Sweetenham J W, Taghipour G, Milligan D, Blystad A K, Caballero D, Fassas A, et al. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20: 745–752
   PubMed Web of Science ®Google Scholar
• Majolino I, Pearce R, Taghipour G, Goldstone A H. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 1997; 15: 509–517
   PubMed Web of Science ®Google Scholar
• Lazarus H M, Rowlings P A, Zhang M J, Vose J M, Armitage J O, Bierman P J, et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 1999; 17: 534–545
   PubMed Web of Science ®Google Scholar
• Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta J J, Garcia-Conde J, et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 2001; 19: 1395–1404
   PubMed Web of Science ®Google Scholar
• Anselmo A P, Cavalieri E, Meloni G, Cantonetti M, Maurizi, Enrici R, et al. Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease. Haematologica 2002; 87: 507–511
   PubMed Web of Science ®Google Scholar
• Stiff P J, Unger J M, Forman S J, McCall A R, LeBlanc M, Nademanee A P, et al. Southwest Oncology Group. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 2003; 9: 529–539
   PubMed Web of Science ®Google Scholar
• Gutierrez-Delgado F, Holmberg L, Hooper H, Petersdorf S, Press O, Maziarz R, et al. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant 2003; 32: 279–285
   PubMed Web of Science ®Google Scholar
• Qazilbash M H, Devetten M P, Abraham J, Lynch J P, Beall C L, Auber M, et al. High-dose therapy and autologous stem cell transplantation in relapsed and refractory Hodgkin's disease: outcome based on a prognostic model. Acta Haematol 2003; 110: 173–178
   PubMed Web of Science ®Google Scholar
• Constans M, Sureda A, Terol M J, Arranz R, Caballero M D, Iriondo A, et al. Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome. Ann Oncol 2003; 14: 745–751
   PubMed Web of Science ®Google Scholar
• Duggan D B, Petroni G R, Johnson J L, Glick J H, Fisher R I, Connors J M, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003; 21: 607–614
   PubMed Web of Science ®Google Scholar
• Chisesi T, Federico M, Levis A, Deliliers G L, Gobbi P G, Santini G, et al. ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial. Ann Oncol 2002; 13(Suppl 1)102–106
   PubMed Web of Science ®Google Scholar
• Horning S J, Hoppe R T, Breslin S, Bartlett N L, Brown B W, Rosenberg S A, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20: 630–637
   PubMed Web of Science ®Google Scholar
• Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386–2395
   PubMed Web of Science ®Google Scholar
• Harrison C N, Gregory W, Hudson G V, Devereux S, Goldstone A H, Hancock B, et al. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. Br J Cancer 1999; 81: 476–483
   PubMed Web of Science ®Google Scholar
• Elghetany M T. Hodgkin's disease coexisting with myelodysplastic syndrome prior to therapy: a case report and a review of the association of Hodgkin's disease with stem cell disorders. Ann Hematol 1997; 75: 231–234
   PubMed Web of Science ®Google Scholar
• Brusamolino E, Anselmo A P, Klersy C, Santoro M, Orlandi E, Pagnucco G, et al. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher after combined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Haematologica 1998; 83: 812–823
   PubMed Web of Science ®Google Scholar
• Cimino G, Papa G, Tura S, Mazza P, Rossi Ferrini P L, Bosi A, et al. Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study. J Clin Oncol 1991; 9: 432–437
   PubMed Web of Science ®Google Scholar